丙型慢性肝病患者血清白细胞介素-10、白细胞介素-12及可溶性白细胞介素-2受体水平

Serum levels of interleukin-10, interleukin-12 and soluble interleukin-2 receptor in chronic liver disease type C.

作者信息

Kitaoka Shuji, Shiota Goshi, Kawasaki Hironaka

机构信息

Second Department of Internal Medicine, Faculty of Medicine, Tottori University, 36-1, Nishi-Machi, Yonago, 683-8504, Japan.

出版信息

Hepatogastroenterology. 2003 Sep-Oct;50(53):1569-74.

PMID:14571788

Abstract

BACKGROUND/AIMS: It is still unclear whether and how Th1/Th2 type cytokines are involved in the progression of chronic liver disease type C. We therefore examined serum levels of IL-10, IL-12 and sIL-2R (soluble IL-2 receptor) in association with clinical parameters in chronic liver disease type C, whereas IL-12 and sIL-2R represent Th1 cytokine and IL-10 does Th2 cytokine, respectively.

METHODOLOGY

Serum levels of IL-10, IL-12 and sIL-2R were measured in 110 patients, including 36 with chronic hepatitis, 24 with liver cirrhosis and 50 with hepatocellular carcinoma in comparison with 19 normal individuals, by an enzyme-linked immunosorbent assay. In 9 chronic hepatitis patients, serum levels of these cytokines were measured before and after interferon therapy. In 28 with hepatocellular carcinoma, they were also measured before and after transcatheter arterial embolization.

RESULTS

Serum levels of IL-10 in chronic hepatitis, liver cirrhosis and hepatocellular carcinoma were 3.9 +/- 1.8 pg/mL, 5.7 +/- 6.4 pg/mL and 5.6 +/- 8.9 pg/mL, respectively. IL-10 level was significantly correlated with level of y-globulin. Serum levels of IL-12 in chronic hepatitis, liver cirrhosis and hepatocellular carcinoma were 347.4 +/- 150.3 pg/mL, 365.2 +/- 130.7 pg/mL and 399.4 +/- 258.2 pg/mL. sIL-2R levels in chronic hepatitis, liver cirrhosis and hepatocellular carcinoma were 614.6 +/- 223.5 U/mL, 878.7 +/- 330.5 U/mL and 1037.9 +/- 412.0 U/mL. Serum levels of IL-12 and sIL-2R were significantly elevated on day 7 after interferon therapy compared to day 0 (p < 0.05 and p < 0.001, respectively), while no significant difference was seen in IL-10. Serum level of IL-10 was significantly elevated on day 3, and that of sIL-2R was elevated on day 3 and 7 after transcatheter arterial embolization, while that of IL-12 was decreased on day 3 and 7.

CONCLUSIONS

The results of the present study suggest that Th1/Th2 type cytokines are changed in association with progression of chronic liver disease type C and in response to therapy.

摘要

背景/目的：目前仍不清楚Th1/Th2型细胞因子是否以及如何参与丙型慢性肝病的进展。因此，我们检测了丙型慢性肝病患者血清中白细胞介素-10（IL-10）、白细胞介素-12（IL-12）和可溶性白细胞介素-2受体（sIL-2R）水平，并分析其与临床参数的关系，其中IL-12和sIL-2R分别代表Th1型细胞因子，IL-10代表Th2型细胞因子。

方法

采用酶联免疫吸附测定法，检测110例患者血清中IL-10、IL-12和sIL-2R水平，其中包括36例慢性肝炎患者、24例肝硬化患者和50例肝细胞癌患者，并与19例正常个体进行比较。对9例慢性肝炎患者在干扰素治疗前后检测这些细胞因子的血清水平。对28例肝细胞癌患者在经动脉导管栓塞治疗前后也进行了检测。

结果

慢性肝炎、肝硬化和肝细胞癌患者血清IL-10水平分别为3.9±1.8 pg/mL、5.7±6.4 pg/mL和5.6±8.9 pg/mL。IL-10水平与γ-球蛋白水平显著相关。慢性肝炎、肝硬化和肝细胞癌患者血清IL-12水平分别为347.4±150.3 pg/mL、365.2±130.7 pg/mL和399.4±258.2 pg/mL。慢性肝炎、肝硬化和肝细胞癌患者sIL-2R水平分别为614.6±223.5 U/mL、878.7±330.5 U/mL和1037.9±412.0 U/mL。与治疗第0天相比，干扰素治疗第7天血清IL-12和sIL-2R水平显著升高（分别为p<0.05和p<0.001），而IL-10无显著差异。经动脉导管栓塞治疗后第3天血清IL-10水平显著升高，第3天和第7天sIL-2R水平升高，而第3天和第7天IL-12水平降低。